A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants

Inclusion Criteria: For all subjects: * Aged between 18 and 79 years (inclusive) with body mass index 18 to 34 kg/m\^2 (both inclusive) * Women without childbearing potential; women of childbearing potential only if the pregnancy test was negative and a combination of condoms with a safe and highly effective contraception method was granted For subjects with renal impairment: * With an estimated glomerular filtration rate (eGFR) \< 90 mL/min/1.73m\^2 determined from a serum creatinine control 2-14 days prior to dosing * Stable renal disease, i.e. a serum creatinine value determined at least 3 months before the pre-study visit should not vary by more than 25% from the serum creatinine value determined at the pre-study visit For healthy subjects: * eGFR ≥ 90 mL/min/1.73m\^2 determined from serum creatinine 2-14 days prior to dosing * Healthy subjects with age-, weight- and gender- matched to renal impaired subjects Exclusion Criteria: For all subjects: * Febrile illness within 1 week before the start of the study * History of severe allergies, non-allergic drug reactions, or multiple drug allergies * Hypersensitivity to the investigational drug, the control agent and/ or to inactive constituents * Regular daily consumption of more than 1/2 liter of usual beer or the equivalent quantity of approximately 20 g of alcohol in another form or more than 1 liter of xanthine-containing beverages or more than 10 cigarettes * Positive testing in the drug screening * Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), human immune deficiency virus antibodies (anti-HIV 1+2) * Donation of more than 100 mL of blood in the preceding 4 weeks or 500 mL in the preceding 3 months * Relevant deviation from the normal range in clinical chemistry, hematology, coagulation or urinalysis as judged by the investigator For subjects with renal impairment * Acute renal failure * Acute nephritis * Any organ transplant in the past 5 years * Severe cerebrovascular or cardiac disorders, e.g. myocardial infarction less than 6 months prior to dosing, congestive heart failure of New York Heart Association grade III or IV, severe arrhythmia requiring anti-arrhythmic treatment * Percutaneous transluminal coronary angioplasty or coronary artery bypass graft less than 6 months prior to dosing * Diagnosed malignancy within the past 5 years * Failure of any other major organ system other than the kidney * Concomitant use of any medication except medications necessary for the treatment of diseases * Diastolic BP \>100 mmHg and/or systolic BP \>180 mmHg * Heart rate below 50 beats/min or above 100 beats/min at screening visit * Significant uncorrected rhythm or conduction disturbances For healthy subjects * Subjects with conspicuous findings in medical history or pre-study examination * A history of relevant diseases of vital organs, of the central nervous system or other organs * Excluded therapies (e.g. physiotherapy, acupuncture, etc.) from 1 week before admission to the ward (-01d) * Use of medication within the 2 weeks preceding the study which could interfere with the investigational product * Systolic BP below 100 mmHg or above 145 mmHg and Diastolic BP below 55 mmHg or above 95 mmHg * Heart rate below 50 beats/min or above 100 beats/min * Clinically relevant findings in the electrocardiogram (ECG)